⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACIU News
AC Immune SA
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
globenewswire.com
ACIU
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
globenewswire.com
ACIU
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
globenewswire.com
ACIU
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
globenewswire.com
ACIU
Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care
globenewswire.com
ACIU
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
globenewswire.com
ACIU
AC Immune First Quarter 2026 Financial and Corporate Updates
globenewswire.com
ACIU
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
globenewswire.com
ACIU
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications
globenewswire.com
ACIU
AZN
BMY